Table 2:
Characteristics of Study Participants (total of 323 patients)
| Control (n = 173) |
Meds (n = 150) |
p-value | |
|---|---|---|---|
| Demographics; n (%) unless otherwise stated | |||
| Age; mean (± SEM) | 43.7 (± 0.9) | 49.4 (± 0.9) | <0.001 |
| Gender (female) | 134 (77.5) | 119 (79.3) | 0.79 |
| White | 141 (81.5) | 121 (80.7) | 0.32 |
| Black or African-American | 6 (3.5) | 11 (7.3) | 0.32 |
| Hispanic/Latino | 21 (12.1) | 16 (10.7) | 0.32 |
| Other Ethnicity | 5 (2.8) | 2 (1) | 0.32 |
| Anthropomorphic; mean (± SEM) | |||
| Baseline weight; (kg) | 131.9 (± 2.3) | 132.8 (± 2.5) | 0.79 |
| Baseline BMI (kg/m2) | 46.9 (± 0.7) | 48.3 (± 0.9) | 0.23 |
| Co-Morbidities; n (%) | |||
| Hypertension | 95 (54.9) | 94 (62.7) | 0.18 |
| Type 2 Diabetes | 68 (39.3) | 67 (44.7) | 0.37 |
| Dyslipidemia | 74 (42.8) | 63 (42.0) | 0.91 |
| Depression | 92 (53.2) | 71 (47.3) | 0.32 |
| Anxiety disorder | 46 (26.6) | 38 (25.3) | 0.89 |
| Bipolar disorder | 4 (2.3) | 6 (4.0) | 0.52 |
| Seizure disorder | 2 (1.2) | 2 (1.3) | 1.00 |
| Weight Affecting Medication; n (%) | |||
| Obesity Protective Medication (i.e. list meds here) |
24 (13.9) | 55 (36.7) | <0.001 |
NOTE: A Fisher Exact test was used for all comparisons (including a single Fisher Exact Test for all the ethnicities) except for all continuous variable comparisons (i.e. age, weight BMI), where a student’s unpaired t-test was used.